The ITP Syndrome: Pathogenic and clinical diversity.

Douglas B. Cines¹,², James B. Bussel³, Howard A. Lieberman⁴, and Eline T. Luning Prak¹

From the Departments of Pathology of Laboratory Medicine¹ and Medicine², University of Pennsylvania; Departments of Pediatrics, Obstetrics-Gynecology, and Medicine, Weill Medical Center³ College of Cornell University³; and Department of Medicine, University of Southern California⁴.

Correspondence to:

Douglas B. Cines, M.D.
Department of Pathology of Laboratory Medicine
University of Pennsylvania
513A Stellar-Chance
422 Curie Boulevard
Philadelphia, PA 19104
(P) 215-662-3966
(F) 215-573-2012
(E) dcines@mail.med.upenn.edu

Running Title: The ITP syndrome
Abstract

Immune thrombocytopenia (ITP) is mediated by platelet autoantibodies that accelerate platelet destruction and inhibit their production. Most cases are considered idiopathic, whereas others are secondary to co-existing conditions. Insights from secondary forms suggest the proclivity to develop platelet-reactive antibodies arises through diverse mechanisms. Variability in natural history and response to therapy suggests that primary ITP is also heterogeneous. Certain cases may be secondary to persistent, sometimes inapparent, infections, accompanied by co-existing antibodies that influence outcome. Alternatively, underlying immunodeficiencies may emerge. Additionally, environmental and genetic factors may impact platelet turnover, propensity to bleed and response to ITP-directed therapy. We review the pathophysiology of several common secondary forms of ITP. We suggest that primary ITP is best thought of as an autoimmune syndrome. Better understanding of pathogenesis and tolerance checkpoint defects leading to autoantibody formation may facilitate patient-specific approaches to diagnosis and management.

INTRODUCTION

Immune thrombocytopenia is mediated by platelet antibodies that accelerate platelet destruction and inhibit their production. The dominant clinical manifestation is bleeding, which correlates generally with severity of the thrombocytopenia. Most cases are considered primary or idiopathic (hereafter designated ITP), whereas others are attributed to co-existing conditions (secondary ITP) (Figure 1).

This categorization implies that ITP is a single clinical-pathological entity. However, variability in natural history and response to therapy suggests that ITP comprises heterogeneous disorders that eventuate in the production of platelet autoantibodies. Certain cases of otherwise "typical ITP" are secondary to persistent, often inapparent infections (e.g. H. pylori or hepatitis C) or are accompanied by co-existing antibodies that might influence outcome (e.g. anti-phospholipid antibodies). Insights from secondary forms (e.g. co-existing immune deficiency and molecular mimicry post-infection) suggest that platelet-reactive antibodies arise through diverse mechanisms. Additionally, environmental and genetic factors may impact platelet turnover, propensity to bleed and response to ITP-directed therapy.
Here, we present an overview of the heterogeneity of antiplatelet-antibody-mediated ITP beginning with diverse immunologic perturbations that might contribute to autoantibody production. We then review the pathophysiology and clinical picture of several secondary forms, placing each into an immunologic context. Finally, we suggest that primary and secondary ITP are best thought of as autoimmune syndromes and that better understanding of their pathogenesis and tolerance checkpoint defects may facilitate disease-specific approaches to diagnosis and management. A text containing a comprehensive list of references is available on-line.

**DIVERSITY OF AUTOIMMUNE MECHANISMS**

**Antibodies, B-cells and T-cells**

Autoantibodies against platelet antigens are considered the diagnostic hallmark of ITP. In some patients, antibodies recognize antigens derived from a single glycoprotein, whereas in others, antibodies recognize multiple glycoproteins. Opsonization by antibody accelerates platelet clearance, but can also alter platelet function and interfere with platelet production. Curiously, platelet antibodies are only detected in ~60% of patients. Failure to detect antibodies might reflect limited test sensitivity, undetected antigens or additional mechanisms of platelet loss. Potential mechanisms that do not implicate B-cells must be reconciled with the >80% initial response rate to IVIG and splenectomy.

T-cells are also implicated in antibody production and thrombocytopenia. Antibodies are usually isotype-switched and harbor somatic mutations, consistent with a T-cell dependent response. The cytokine profile is reported to be consistent with CD4+ Th0/Th1 activation, including increased prevalence of the TNFα (+252) G/G phenotype. In one study, the Th1/Th2 cytokine mRNA ratio correlated inversely with the platelet count, although the study was neither prospective nor restricted to untreated patients at presentation. T-cell subset polarization has been attributed to reduced peripheral Th2 cells and Tc2 cells or number or function of CD25brightFoxp3+ T-regulatory cells. Decreased Fas expression on Th1 and Th2 cells, increased expression of Bcl-2 mRNA and reduced Bax mRNA on CD4-cells may each contribute to a breakdown in T-cell tolerance. Moreover, TGFβ expression (which is associated with an immunosuppressive Th3 profile) correlates with disease activity.
Tolerance checkpoint defects in immune thrombocytopenia

The lymphocyte repertoire is monitored and purged of autoreactive specificities that arise at different stages of development. The repertoire is also influenced by homeostatic mechanisms that control peripheral compartment size and subset distribution, e.g. by cytokine B-cell activating factor BAFF (BLyS). Increased prevalence of the (-871) TT genotype of the BAFF promoter, accompanied by increased serum BAFF, has been reported in ITP\textsuperscript{10}.

It is unclear how B- and T-cell tolerance is perturbed in primary or secondary ITP. Nevertheless, we propose that the immune tolerance defects in ITP can be classified descriptively into three categories: those arising during early development or in the bone marrow (central tolerance defects), differentiation blocks with skewed peripheral B-cell subsets, and peripheral tolerance defects arising in the setting of immune stimulation (Figure 2). We hypothesize that immune thrombocytopenia resulting from defects in peripheral tolerance checkpoints is more likely to be platelet-specific and responsive to ITP-therapy or antigen elimination (Figure 3). Given the relative specificity of the immune response, autoreactivity is less likely to be resurrected rapidly, although this may occur with late relapses. Conversely, central tolerance defects are likely to involve additional cell types and be less responsive to immune-directed therapy because a large proportion of the primary repertoire is autoreactive and may be reconstituted rapidly following therapy\textsuperscript{11,12}. Below we discuss the secondary forms of ITP based on purported immunologic defects and consider how this tolerance checkpoint classification might shed insight into the heterogeneity of primary ITP.

DIVERSITY OF SECONDARY ITP

Our thesis is that the various forms of secondary ITP have different immunologic underpinnings and that a better understanding of the responsible mechanisms could lead to improved, targeted treatment. Each section emphasizes the immunologic abnormalities, with each disorder considered in order of responsiveness, starting with the self-limited. We then consider responsive syndromes with a course similar to primary ITP and end with the most diverse and least responsive disorders that might be caused by defects in central tolerance.
Self-limited and highly responsive forms of secondary ITP

Acute ITP of childhood.

Approximately two-thirds of children with ITP experience a preceding febrile illness. ITP has been attributed to production of platelets expressing viral antigens, binding of immune complexes, generation of anti-viral antibodies cross-reactive with platelet antigens, and formation of autoantibodies through epitope spread\(^\text{13}\). Thrombocytopenia during the viremic phase may also result from infection of megakaryocytes, altered platelet surfaces that accelerate clearance, hemophagocytosis, disseminated intravascular coagulation, or a microangiopathic syndrome. Eighty percent of children remit within 6-12 months\(^\text{14}\).

Measles-Mumps-Rubella (MMR) vaccine (ITP-MMR).

Acute ITP occurs after vaccinations against several infectious agents. Best studied is MMR vaccination, but there is reasonable documentation for acute thrombocytopenia developing after vaccination against pneumococcus, \(H\) influenzae \(B\), hepatitis B and Varicella Zoster Virus.

The estimated incidence of ITP-MMR is 1/40,000 doses, defined as thrombocytopenia developing within 42 days of exposure\(^\text{15}\), an incidence 6-fold higher than pediatric ITP. Most cases occur after initial vaccination during the second year of life and there is a male predominance\(^\text{15,16}\). Thrombocytopenia is often severe\(^\text{16}\) but responsive to IVIG or corticosteroids. Over 80% recover within 2 months, typically within 2-3 weeks\(^\text{16}\), with less than 10% evolving into chronic ITP\(^\text{17}\), simulating the pattern of acute ITP of childhood\(^\text{18}\). The pathophysiology is unknown, although antibodies to GPIIb/IIIa have been identified in few patients\(^\text{19}\), similar to primary ITP. Patients in remission or with stable ITP may receive all recommended immunizations\(^\text{15,16}\), as the incidence of ITP-MMR is 10-20-fold lower than after natural infection. Delays in vaccination are appropriate during resolution of acute ITP or immunosuppressive treatment. The CDC Advisory Committee on Immunization Practices has recommended assessing immunity to determine the need for revaccination, although recurrence of thrombocytopenia after re-vaccination is rare\(^\text{15}\).
Helicobacter pylori (HP) (ITP-HP).

There is strong evidence for an association between infection with H. pylori (HP) and ITP\textsuperscript{20,21}. Active infection is diagnosed using the \textsuperscript{13}C-urea breath test, finding bacterial antigen in stool or with gastric biopsy. Antibody testing is insensitive, does not prove active infection and false positives occur after IVIG.

ITP-HP is defined retrospectively by a durable platelet response to bacterial eradication. Pathogenesis has been attributed to molecular mimicry whereby HP induces antibodies that cross-react with platelets\textsuperscript{21,22}. HP strains show considerable geographic variation in the cagA virulence gene, which seems to correlate with the incidence of ITP-HP\textsuperscript{22,23}. In one study, platelet eluates from ITP-HP patients cross-reacted with cagA, recognizing a 55kDa antigen on ITP-HP platelets, but not on platelets from healthy controls\textsuperscript{22}.

The prevalence of HP infection among ITP patients is comparable to the general population matched for age and location\textsuperscript{20,21}, although only a small fraction of infected patients develop ITP-HP. Platelet response to documented bacterial eradication ranges from 0\%-7\% in two U.S. series to 100\% in one Japanese series\textsuperscript{20}. The benefit of bacterial eradication has been established compared to unsuccessful or no eradication\textsuperscript{20}. Failure to correct thrombocytopenia correlates with T-cell and B-cell clonality, consistent with the emergence of antigen-independent autoreactive clones (Figure 4). H. pylori infection may alter the balance between activating and inhibiting FcγR's\textsuperscript{24}. Platelet levels often rise within 1 to 3 weeks of antibiotics, before an effect on antibody would be predicted, perhaps attributable to a restoration in this balance. Given the low costs, noninvasive diagnostic methods, and favorable toxicity profile compared to standard ITP therapy, detection and treatment should be considered primarily in populations with a high background incidence of HP, in whom there is a high rate of platelet response to bacterial eradication.

Cytomegalovirus (ITP-CMV).

CMV commonly causes severe congenital thrombocytopenia and delayed platelet recovery after bone marrow transplantation. CMV can infect megakaryocytes, progenitor cells and supporting stroma\textsuperscript{25}. An acute ITP-like syndrome occurs in immunocompetent and immunosuppressed individuals. In one series, 3 of 28 children and 3 of 80 adults with typical ITP had CMV in their urine but there was no correlation
between urinary viral clearance and resolution of thrombocytopenia\textsuperscript{26}, while in another study, platelet counts improved in 4 refractory patients following treatment for CMV\textsuperscript{27}.

\textit{Varicella Zoster Virus (ITP-VZV)}.

Approximately 5\% of otherwise healthy children hospitalized with primary VZV develop severe thrombocytopenia. Thrombocytopenia occurs in neonates delivered to infected mothers, post-vaccination and during viral reactivation\textsuperscript{28}. Within 5 days of the exanthem, patients present with abrupt onset of bleeding, prominent at extracutaneous sites. Thrombocytopenia may be caused by viral damage to megakaryocytes, adsorption of viral antigens onto platelets or desialylation of platelet glycoproteins. Thrombocytopenia can be a harbinger of viral dissemination, which can eventuate in purpura fulminans. Exposure to corticosteroids within the preceding three months may increase this risk. Spontaneous resolution in non-fulminant cases generally occurs within 2 weeks\textsuperscript{28}. The utility of antiviral therapy in hastening resolution of thrombocytopenia is unproven.

Less often, thrombocytopenia develops days to several weeks after resolution of infection and is characterized by reduced platelet survival with a normal appearing bone marrow (ITP-VZV)\textsuperscript{29}. Antibodies to known platelet glycoproteins and uncharacterized platelet antigens that do not cross-react with VZV have been demonstrated\textsuperscript{30}. Complement-fixing antiviral antibodies that cross-react with \textasciitilde 50kD and \textasciitilde 100kD antigens on normal platelets disappear as the infection resolves. ITP-VZV typically resolves spontaneously within 1-3 weeks\textsuperscript{28,31}. Occasionally, the course is protracted and requires ITP-therapy\textsuperscript{28}.

\textit{Hepatitis C (ITP-HCV)}.

HCV is perhaps the most common chronic viral infection, affecting \textasciitilde 175 million persons worldwide. Serologic evidence of HCV was found in 159/799 (20\%) of ITP patients in six cross-sectional studies from various countries including the U.S.\textsuperscript{21}. Conversely, the incidence of ITP in newly diagnosed HCV patients is higher than expected\textsuperscript{32}.

The pathophysiology of HCV-associated thrombocytopenia (HCV-TP) is poorly understood and likely multifactorial. The HCV structural protein E2 activates polyclonal B-cells by binding to CD81, part of the B-cell co-receptor\textsuperscript{33}, predisposing to clonal expansion of IgM\textsuperscript{+}\kappa\textsuperscript{+}\textit{IgD}\textasciitilde \textit{CD21}\textasciitilde \textit{CD27}\textsuper{+} B-cells\textsuperscript{34}. Anti-platelet glycoprotein antibodies
are common, even without thrombocytopenia. Anti-viral antibodies, cross-reactive with GPIIIa, have been identified\textsuperscript{35}.

Production of thrombopoietin may be reduced with advanced disease. Infection of megakaryocytes\textsuperscript{36} may impair platelet production further. In the U.S. experience, HCV-positive patients were older, more often male, and had less severe thrombocytopenia, but more major bleeding than did those with ITP\textsuperscript{37}. In other countries, the clinical characteristics of ITP-HCV were similar to ITP\textsuperscript{21}. Poor response to corticosteroids was seen in one study, whereas in others response rates exceeded 50\%\textsuperscript{21,38}. Prednisone may increase viral load, hepatic transaminases and bilirubin\textsuperscript{37}. IVIG, anti-RhD Ig and splenectomy are effective, as in ITP\textsuperscript{37}. In adults receiving IFN-\(\alpha\) therapy, platelet counts decrease initially because of impaired production, but eventually increase in ~50\%\textsuperscript{37}. Initially low platelet counts increased to >100x10\(^9\)/L in 21 of 23 patients receiving 75 mg daily of an oral thrombopoietin receptor agonist (eltrombopag), permitting subsequent combined therapy with PEG-INF-\(\alpha\), ribavirin, and eltrombopag\textsuperscript{39}.

Screening is appropriate in patients with risk factors (multiple sex partners, intravenous drug abuse, blood transfusions) or where the background prevalence of infection is high. Corticosteroids should be avoided or discontinued. Anti-HCV combined with ITP-specific therapy should be considered, even without overt liver disease\textsuperscript{21,37,39}.

\textit{Human immunodeficiency virus (ITP-HIV)}.

ITP-HIV (platelet count <150x10\(^9\)/L) was reported in 5\%-30\% of infected patients prior to the introduction of highly active antiretroviral therapy (HAART)\textsuperscript{21}. The 1-year incidence of ITP-HIV (platelet count <50x10\(^9\)/L) was 3.7\% among 36,515 participants in the Multistate Adult and Adolescent Spectrum of Disease Project, which increased in frequency and severity with disease progression (1.7\% without AIDS, 3.1\% with immunologic AIDS (CD4 lymphocytes<200/\(\mu\)L) and 8.7\% with clinical AIDS)\textsuperscript{40}.

Multiple mechanisms contribute to ITP-HIV, including accelerated platelet clearance and suppressed platelet production. Sera contain antibodies against viral proteins (nef, gag, env, pol, GP160 and p24), some of which cross-react with amino acids 44-66 of GPIIIa. Anti-idiotypic antibodies have also been identified that prevent thrombocytopenia from developing \textit{in vivo}\textsuperscript{41}. Anti-GPIIb/IIIa antibodies fragment platelets by activating NADPH oxidase, generating peroxide and other reactive oxygen species through platelet phospholipase A2 and 12-lipoxygenase\textsuperscript{42}; fragmentation is
inhibited by dexamethasone, which impedes enzyme translocation to and from the membrane. Megakaryocytes express CD4 and co-receptors for HIV, internalize HIV and express viral RNA\(^{43}\). During disease progression, impaired platelet production by cytopathic infection of megakaryocytes predominates\(^{44,45}\). The centrality of viral antigens in the pathogenesis of thrombocytopenia is supported by the response of the platelet count to HAART.

Patients may present with isolated thrombocytopenia indistinguishable from ITP years before developing AIDS\(^{21,40}\). As the disease progresses, the prevalence and severity of thrombocytopenia correlates with viral load and response to HAART\(^{46,47}\). ITP-HIV generally responds to ITP-therapy. Short-term treatment with prednisone appears safe and effective, as does splenectomy\(^{48,49}\). Higher response rates and prolonged responses are more common with anti-D than with IVIG\(^{50}\). Response rates are lower among intravenous drug users, possibly reflecting co-infection with HCV.

**Differentiation blocks in secondary ITP**

*Chronic lymphocytic leukemia (ITP-CLL) and Hodgkin’s disease (ITP-HD).*

The most common neoplastic processes linked to ITP involve the hematopoietic compartment, although rare patients with solid tumors have been reported. ITP develops in 1-5% of patients with CLL, an incidence approximately one-tenth that of autoimmune hemolytic anemia (AHA)\(^{51-53}\). Older age and advanced stage are independent risk factors for AHA, but the predictive value of these risk factors for ITP-CLL is less apparent\(^{54}\). ITP occurs a mean of 13 months from the diagnosis of CLL, but may precede it or develop at any time. Indeed, small CD19/CD5 positive clones may be found in bone marrow from older patients with ITP\(^{51,55}\).

ITP-CLL is associated with a higher frequency of unmutated IgV\(_{H}\) genes, more frequent involvement of the V\(_{H}\)1 family, and shorter 5-year survival\(^{54}\). There is no evidence the malignant clone is responsible for antibody production. ITP-CLL may also be precipitated by fludarabine or other purine analogues that accelerate loss of CD4+, CD45RA+ cells\(^{53}\). There is concern about using purine analogues to treat ITP based on experience in AHA\(^{53}\). ITP-CLL is somewhat less responsive to IVIG and prednisone\(^{54}\), but promising results have been obtained with rituximab and cyclosporine\(^{53}\).

The prevalence of ITP-HD is estimated at 0.2-1%, with most cases occurring after the diagnosis of HD\(^{56,57}\). In the British National Lymphoma Investigation Registry, 8
of 4090 patients with HD developed ITP after a median of 23 months (3-57), including 6 in remission\textsuperscript{58}. ITP often responds to treatment of HD and is rare in patients who have been in remission for many years. ITP is estimated to occur in 0.76\% of patients with NHL without CLL and often precedes the diagnosis of lymphoma (n=1,850 NHL patients)\textsuperscript{59}.

\textit{Large granular T-lymphocyte leukemia (ITP-LGL)}

LGL is a clonal proliferation of mature CD8+ T-lymphocytes. Clonal populations of LGL cells are also detected in some patients with rheumatoid arthritis and modest increases occur in some patients with ITP\textsuperscript{60}. Neutropenia, anemia and mild thrombocytopenia are common in LGL-leukemia. It is not clear if the mechanisms underlying ITP in LGL leukemia, wherein LGL clonality and increases in the absolute CD8 count are sustained, are similar to reactive conditions in which the LGL count may be transiently or cyclically elevated\textsuperscript{61}. Severe thrombocytopenia, observed in \textasciitilde1\% \textsuperscript{60}, may result from suppression of megakaryopoiesis by LGL-mediated cytotoxicity\textsuperscript{62}. Treatment is directed against the LGL clone, employing cyclophosphamide or cyclosporine\textsuperscript{60,62}.

\textit{Common variable immune-deficiency (ITP-CVID)}.

CVID is an uncommon (1 in 50,000 persons) heterogeneous disorder characterized by defects in late stages of B-cell development. Clinical manifestations include recurrent infection, allergy, and autoimmunity. The diagnosis is established by persistent reduction in serum immunoglobulins and insufficient antibody response to protein and polysaccharide antigens. Recurrent sino-pulmonary tract infections or systemic granulomas occur in 70\%-80\% of patients. Recognition is often delayed because of diverse and subtle symptoms. Mortality is generally related to progressive bronchiectasis or pulmonary granulomas or the development of lymphomas, the latter being more common in women over 60 years of age.

Over 20\% of patients develop an autoimmune disorder, most commonly involving hematopoietic cells. ITP, often severe (median platelet count 20x10\textsuperscript{9}/L), occurs in \textasciitilde10\% of patients, often accompanied by AHA and occasionally autoimmune neutropenia\textsuperscript{63,64}. There is no gender predilection. The median age at onset of ITP is approximately 23 years, but may occur at any age\textsuperscript{65}. Disease onset precedes the diagnosis of CVID by a
mean of 4 years\textsuperscript{64,66}, but may also be diagnosed contemporaneously or after treatment for CVID has begun.

The pathogenesis of autoantibody production is unknown. Studies in small numbers of CVID patients suggest that defects at either of two B-cell tolerance checkpoints contribute to autoantibody production. Polymorphisms in the B-cell transmembrane activator and calcium-modulating interactor (TACI) are linked to CVID, and especially to development of ITP or AHA\textsuperscript{67}. In other studies, the propensity to develop ITP or AIHA correlates with a deficiency in isotype-switched memory B-cells (CD27\textsuperscript+/IgM\textsuperscript-/IgD\textsuperscript{−})\textsuperscript{68}. An associated inability to eradicate microbes is posited to exacerbate tissue damage, expanding production of cross-reactive antibodies in the face of deficient T- or B-cell peripheral control mechanisms. IVIG therapy may promote upregulation of regulatory T-cells\textsuperscript{69}. ITP is also associated with other immunodeficiency states, including DiGeorge syndrome, IgA and complement (C4) deficiency and probably Wiskott-Aldrich syndrome, but not Bruton’s X-linked agammaglobulinemia where B-cells are absent.

CVID-ITP patients respond to corticosteroids, IVIG and anti-D\textsuperscript{64}, but prolonged steroid use is associated with fungal infections and the use of anti-D may be precluded by concurrent AHA. Hence, IVIG is the mainstay of therapy. Rarely anaphylaxis due to IgE-anti-IgA antibodies necessitates the use of IgA-depleted IVIG preparations. Two-thirds of patients respond initially to splenectomy, but concern over sepsis complicates the decision to operate or to use immunosuppression\textsuperscript{63,64,70}. Rituximab combined with IVIG appears beneficial in some patients\textsuperscript{70}. Fewer patients develop ITP while on IgG replacement\textsuperscript{63,64}, suggesting that early diagnosis and therapy are useful\textsuperscript{63}.

Central Tolerance Defects in Secondary forms of ITP

Autoimmune lymphoproliferative (Canale-Smith) syndrome (ITP-ALPS).

ALPS is an inherited disorder characterized by defective B- and T-lymphocyte apoptosis. Eighty-five percent of patients have mutations in the APTI gene encoding Fas (CD95/Apo-1); others have mutations in genes encoding Fas ligand (Fas-L), caspase-8 or -10; the underlying defect has not been identified in the remainder. Criteria for diagnosis include chronic non-malignant lymphadenopathy and (hepato)splenomegaly, defective Fas-mediated T-cell apoptosis and >1% TCR\textalpha/\textbeta+, CD3+, CD4+, CD8- (double negative) T-cells in peripheral blood or lymphoid tissue\textsuperscript{71}. 
Supporting features include autoantibodies and a family history of ALPS. The median age at presentation is 2-3 years, but the disease can present (rarely) in adulthood.

Homzygous deletion of Fas or Fas-L in lpr and gld mice, respectively, leads to lymphoproliferation and autoimmunity, but not to immune cytopenias. Expression of clinical disease in humans is more complex. Although defects are most commonly inherited in an autosomal dominant fashion, penetrance is variable. Clinical expression correlates with dominant negative mutations that interfere with ligand/receptor trimerization and signal transduction. The observation of healthy family members with similar mutations and in vitro defects suggests involvement of additional genes or environmental factors (e.g. altered IL-2/IL-2 receptor regulation leading to loss of CD25+/CD4+ T-cells\(^72\), among others). B-cells express Fas when activated, becoming sensitive to killing by Fas L-expressing T-cells. However, the pathophysiological relationship between these mutations and the tendency to form autoantibodies to hematopoietic cells is not established.

Hepatosplenomegaly, and to some extent lymphadenopathy, tends to regress, whereas autoimmunity typically persists. Approximately 20% develop ITP and/or AHA (blurring the distinction between ITP-ALPS and Evans Syndrome, i.e. ITP-ES\(^71\)) and/or neutropenia, presumed immune in origin\(^72\). Thrombocytopenia responds less well than primary ITP to corticosteroids, IVIG or splenectomy and immunosuppression may increase the risk of infection. Initial experiences with rituximab\(^73\) and mycophenolate mofetil\(^74\) are promising. Responses to pyrimethamine/sulfadoxine and bone marrow transplantation are reported. Progressive hypogammaglobulinemia may develop into a picture similar to CVID. Patients have a propensity to develop B-cell lymphomas.

**Evans Syndrome (ITP-ES).**

ITP-ES (co-incidence of ITP and warm AHA) occurs in ~0.7% of patients with ITP\(^75\). There is no gender preference. Thrombocytopenia can precede the development of AHA by years, delaying diagnosis, occur concomitantly, or develop sometime thereafter. Approximately 50% of ITP-ES patients develop neutropenia and 5-10% develop pancytopenia\(^75,76\). The red cell antibodies are directed at the Rh locus with rare exceptions and are serologically distinct from platelet-reactive antibodies. ITP-ES may follow bone marrow or solid organ transplantation, exposure to fludarabine or other drugs, and in association with SLE, CLL and ALPS. Elution studies are needed to distinguish autoantibodies from prior therapy with anti-D.
New evidence suggests that ITP-ES may involve broader autoimmunity with partial penetrance. In one study, 50-60% of ITP-ES children met criteria for ALPS\textsuperscript{71}. IgG or IgA deficiency, eczema, alopecia or other autoimmune conditions may develop.

ITP-ES often follows a remitting-relapsing course or cytopenias may persist. Responses and exacerbations of AHA and ITP are often discordant; immune hemolysis may protect platelets from phagocytosis. Responses to corticosteroids and IVIG are transient and splenectomy is often ineffective\textsuperscript{77}. Therefore, early recognition is important as somewhat higher response rates are reported with combination therapy, rituximab, cyclosporine or MMF\textsuperscript{78,79} and some respond to transplantation. Nevertheless, mortality rates may approach 30-35% due to hemorrhage or sepsis\textsuperscript{75}.

\textit{Anti-phospholipid syndrome (ITP-APS).}

Many patients present with thrombocytopenia and antiphospholipid antibodies (APLA). When both are present, three questions arise: 1) Does thrombocytopenia result from activation of coagulation or from platelet antibodies? 2) Do APLA identify patients at risk for thrombosis? and 3) Should treatment be altered?

APS is defined by venous or arterial thrombosis or recurrent pregnancy loss in the presence of APLA (lupus anticoagulant or high titers of anti-cardiolipin or anti-\(\beta\)2-GPI-1 antibodies on at least two measurements made at least 12 weeks apart). APS may be secondary to SLE or related disorders or primary when no underlying disorder is apparent. Approximately one-third of patients with primary APS develop thrombocytopenia, generally mild to moderate. Severe thrombocytopenia may correlate with risk of thrombosis\textsuperscript{80}. Platelets may rise in response to anticoagulation given for a systemic thrombotic diathesis (catastrophic APS). Patients with thrombocytopenia and anti-prothrombin antibodies are susceptible to bleeding.

Several proposed mechanisms contribute to immune thrombocytopenia. APLA bind anionic phospholipids and diverse phospholipid-binding proteins, e.g. beta-2-glycoprotein I (\(\beta\)2-GPI-1), with low affinity. Anti-\(\beta\)2-GPI-1 antibodies dimerize the antigen, which increases the avidity of antibody binding. Anti-\(\beta\)2-GPI-1 forms complexes between GPIb\(\alpha\) and a splice variant of the apolipoprotein E receptor 2 (apoER2\textsuperscript{'+')}\textsuperscript{81-83}. Cross-linking of anti-\(\beta\)2-GPI-1 stimulates phosphorylation of apoER2\textsuperscript{'+'}, activates p38 MAP kinase, generates thromboxane A2 and activates phosphatidylinositol-3-kinase and Akt pathways through GPIb\(\alpha\), sensitizing platelets to other agonists. Some APLA bind to anionic epitopes on GPIIIa, while others recognize phosphatidylserine.
translocated from the inner to the external plasma membrane when platelets are activated, creating a positive feedback loop.

It is uncertain if APLAs accelerate platelet clearance *in vivo*. Serologically distinct anti-platelet GP antibodies with specificities seen in ITP are also found in APS and these correlate with thrombocytopenia more closely than APLA. Moreover, 10-70% of patients with ITP have one or more APLA, depending on disease activity and the extent of the search.

There is no compelling reason to assess patients with typical ITP for APLA. APLA do not alter response to ITP therapy. It is uncertain whether APLA increase the risk of thrombosis during response to ITP therapy. Although finding APLA per se does not alter management of primary ITP, patients with APS may require higher platelet counts than are otherwise necessary (>40-50x10⁹/L) to manage anticoagulation used to prevent thrombosis or fetal loss.

*Systemic lupus erythematosus (ITP-SLE).*

Thrombocytopenia, generally not severe, develops in approximately one-third of SLE patients at some time during their illness, while SLE develops in 2-5% of ITP patients (usually female) who are followed for years.

The pathogenesis of thrombocytopenia is multifactorial and includes antibodies to platelet glycoproteins (as in ITP), DNA, phospholipids and phospholipid binding proteins, CD40 ligand, TPO and its receptor, immune complexes of diverse composition, and impaired FAS-FAS ligand-mediated apoptosis. Thrombocytopenia may also be caused or exacerbated by systemic vasculitis, hemophagocytosis, thrombotic microangiopathy, amegakaryocytosis and marrow damage.

The clinical course and response to medical management of isolated thrombocytopenia is similar to ITP, whereas severe thrombocytopenia that develops during an exacerbation of vasculitis portends a poorer prognosis, requiring aggressive treatment of the underlying disease. Maintenance treatment should be limited to prevention of bleeding. Patients with severe SLE are less likely to respond to splenectomy than those with primary ITP. Reliance on splenectomy should be tempered by frequent requirements for corticosteroids or immunosuppressants to control other manifestations of SLE and is indicated when thrombocytopenia is severe, persistent, is the predominant reason for treatment, or if other tolerable options are ineffective and the underlying disease is otherwise controlled.
Post-transplantation (ITP-Tx)

ITP and ITP-ES may develop after allogeneic or autologous bone marrow, umbilical cord progenitor cell, peripheral blood and solid organ transplantation. ITP-Tx is a heterogeneous entity with an onset from one day to over a year post-procedure and with a clinical course spanning unresponsive, relentless and fatal, to one typical of chronic ITP or spontaneous resolution. The best documented cases result from mixed chimerism with host alloantibodies directed to polymorphic determinants on donor platelets, e.g. HPA-1a. Less commonly, the donor had overt or presumptive ITP or autoantibodies develop de novo in the context of immunosuppression and chronic infection. Thrombocytopenia in this setting may result from GVHD or persistent infection, e.g. CMV, which require different approaches to management.

HETEROGENEITY OF PRIMARY ITP

Variation in pathogenesis and management of secondary forms of ITP may provide insight into the heterogeneity of what is currently designated “primary ITP”, a diagnosis of exclusion. Much of what follows is speculative because definitive studies have not been completed in a number of areas.

Consensus guidelines for primary ITP refer to patients with isolated thrombocytopenia (platelet counts <150x10^9/L). However, only 7% of 217 individuals meeting these criteria with platelets between 100-150x10^9/L developed more severe thrombocytopenia over a mean of 64 months; platelets normalized without intervention in 11% and remained stable in the rest. Other explanations may exist for mild thrombocytopenia meeting the criteria of ITP and it may be inappropriate to presume the diagnosis in this setting.

Recent surveillance studies challenge the long-held notion that ITP is predominantly a disorder of young women; rather, the disease was reported to show a progressive increase in incidence with age and a gender balance in the older population, with mean platelets counts of ~20x10^9/L, excluding incidental detection during other investigation. It is unclear whether these findings reflect changes in demographics or better detection, because population-based studies were unavailable prior to 2000. The demographics of ITP may be mutable and show regional differences due to emergence of predisposing infections, increase in immune deficiency in aging populations and increased survival from B-cell neoplasms.
Initiation of the immune response.

The prevalence of ITP after infections that prompt production of cross-reactive antibodies (e.g. HIV, HCV, H. pylori) association with diverse immunodeficiency states (e.g. CLL, CVID and ALPS), and the co-occurrence of specific autoantibodies (ES, APS) suggests the predisposition to form platelet autoantibodies results from several mechanisms.

Molecular mimicry. As discussed, some cases of ITP-HIV, ITP-VZV and ITP-HCV are associated with anti-viral antibodies that cross-react with platelet GPIIb/IIIa. The variable incidence of ITP-HP has been attributed to variation in virulence genes that evoke cross-reactive antibodies. The clinical course of ITP-MMR and acute ITP in childhood suggests a similar etiology.

Perturbation of the immune repertoire. Although platelet glycoproteins are subject to proteolysis, post-translational modification, internalization and shedding, no intrinsic or acquired abnormalities have been identified to cause platelets to appear as foreign to the immune system. GPIIb/IIIa is expressed on thymic epithelial cells and no intrathymic defect in tolerizing high-affinity autoreactive T-cell clones has been identified. It is also not known if some patients with ITP have a central B-cell tolerance defect or whether loss of peripheral tolerance mediates acute or chronic ITP. As yet unidentified exogenous antigens might induce loss of peripheral tolerance and promote development of self-reactive antibodies in settings where proinflammatory cytokines and IFNγ are upregulated or counter-regulatory processes are disrupted through loss of T-regulatory cells, failures in B-cell tolerance or alterations in cytokines or chemokines.

As discussed, patients often have a cytokine profile consistent with CD4+ Th0/Th1 activation associated with reduced peripheral Th2 and T-regulatory cells and impaired susceptibility to apoptosis. Although this pattern promotes antigen presentation and might amplify and propagate self-reactive clones, it is neither specific for ITP nor universal. There is as yet limited evidence that T-cell defects precede the onset of disease105, anticipate clinical course5, provide prognostic information, or modify response. Reversion to a Th0/Th2 cytokine gene profile after treatment with IVIG correlates with remission in childhood ITP106 and Foxp3 mRNA and the T cell receptor
Vβ repertoires normalize in splenectomy or rituximab responders, raising uncertainty about causation versus effect of therapy.

Amplification of the autoimmune response.

Platelets are involved in inflammation and innate immunity. ITP T-cells recognize cryptic epitopes generated from GPIIb/IIIa and likely other platelet proteins. The hierarchy of peptides recognized by T-cells varies, and only some are recognized by T-cells from healthy controls\textsuperscript{107}. Are these peptides generated by inflammatory stimuli or platelet turnover accelerating normal pathways of cellular processing in APCs or might minor pathways generate novel immunogenetic peptides under these conditions?

ITP antibodies also vary in antigen specificity\textsuperscript{1}. Limited epitope spread, whereby antigen processing initiated by antibody to one platelet determinant promotes generation of additional antigens derived from other platelet proteins\textsuperscript{13}, is suggested by the multiplicity of structurally distinct platelet-specific epitopes that become targets, the diversity of immunogenic peptides recognized, and the development of T-cell clones that recognize transmembrane and cytoplasmic determinants\textsuperscript{107}. Platelets may augment this process when they: 1) undergo apoptosis\textsuperscript{108}, 2) are activated by antibody to express MHC II\textsuperscript{109}, CD154 (CD40L)\textsuperscript{110} and CD80 (B7-1), 3) release sCD40L and proinflammatory cytokines (e.g. MCP-1 and RANTES), or 4) by immune complex-mediated activation of APCs\textsuperscript{108} via Fcγ receptors.

Auxiliary pathways.

Platelet antibodies are not detected in all patients and anti-CD20 (and other immunosuppressive agents) only induce durable complete remission in the minority notwithstanding prolonged and extensive depression in circulating B-cells. Plasma cells and some tissue-based B-cell populations are resistant to depletion. In addition, loss of B-cell antigen presentation may not correct defects in central tolerance and T-cell education. Moreover, CD8+ cytotoxic T-cells, which in some patients express increased Apo-1/Fas, granzymes A and B, perforin, and reduced killer cell Ig-like receptors, can lyse platelets \textit{in vitro}\textsuperscript{111}. Increased numbers of VLA-4+ CD3+ C8+ T-cells expressing the homing receptor CX3CR1 were found in ITP bone marrow\textsuperscript{112}. It is uncertain whether these findings precede disease onset, whether sufficient effector:target ratios are attained to impair platelet production, and how often these findings impact the clinical picture.
Evolution of the immune response.

The clinical course of ITP is variable. Some patients relapse months to years after splenectomy-induced remission, whereas others develop hemostatic platelet counts years after failing diverse modalities\(^\text{113}\). This suggests an unstable balance between antibody production and containment, immune complex clearance and platelet production, especially evident in patients with cyclic immune thrombocytopenia. The presence of oligoclonal peripheral T-cell populations, defined by CDR3 spectratyping, appears to correlate directly with disease duration\(^6\) and inversely with response to splenectomy\(^114\) and rituximab\(^6\). Peptides recognized by ITP T-cells also change over time, with implications for induction of tolerance\(^\text{107}\). GPIIb/IIIa-reactive antibodies cloned from ITP spleens show a pattern consistent with limited \(V_\text{H}\) gene usage but also with antigen-driven somatic mutation\(^3\). Somatic mutations in anti-pathogen antibodies accompanied by clonal exhaustion could cause autonomous clones to emerge that do not resolve upon successful elimination of inciting antigen (e.g. \textit{H. pylori} Figure 4)\(^{115}\). Mechanisms mediating remission in childhood ITP are unstudied.

Variations in pathogenesis of thrombocytopenia.

Enhanced platelet clearance. Approximately two-thirds of patients achieve a durable response to splenectomy. But what of the one-third who fail including those who relapse years later? Platelet antibodies have not been shown to predict response to any intervention. Nor is it known whether impaired platelet production is responsible. Fc\(\gamma\)RIIc expression, involved in ADCC, is more prevalent in ITP patients. Response to corticosteroids is affected by polymorphisms in Fc\(\gamma\)RIIa. Fc\(\gamma\)R-mediated phagocytosis is upregulated by platelet-bound LPS\(^\text{116}\) and likely other intermittent environmental stimuli (e.g. hormones), and downregulated by platelet CD47. Antibody-mediated platelet activation may accelerate clearance through apoptosis or opsonization by inducing signals such as phosphatidylserine or P-selectin-PSGL1. Anti-GPIIIa antibodies in ITP-HIV lyse platelets through a peroxide-mediated process. Hyperthyroidism, present in \(~5\%\) of ITP patients, is associated with reduced platelet survival; platelet counts improve once a euthyroid state is restored\(^\text{117}\).

Impaired platelet production. Platelet production is variably impaired\(^\text{118}\), possibly contributing to failure of splenectomy or therapy directed at attenuating peripheral
clearance. Antibodies may impair megakaryocyte development, induce apoptosis, impede platelet release or promote intramedullary phagocytosis\textsuperscript{118}. ITP plasmas differ in their ability to inhibit megakaryopoiesis \textit{in vitro}\textsuperscript{119}, in part related to differences in antigen specificity. The effects of cytolytic T-cells or ADCC on platelet production, especially in refractory disease, are uncertain. Genetic or acquired limitations in megakaryocyte and platelet production, susceptibility to antibody- or cell-mediated intramedullary apoptosis\textsuperscript{120}, or heterogeneity in intracellular signal transduction pathways are largely unexplored.

\textit{Clinical heterogeneity.}

\textit{Propensity to bleed.} Some patients develop recurrent epistaxis, frequent ecchymoses or other bleeding manifestations at platelet counts of 20x10\textsuperscript{9}/L, whereas others rarely bleed, notwithstanding values below 5x10\textsuperscript{9}/L. Infrequently, ITP antibodies initiate antigen shedding and inhibit specific glycoprotein functions. It is unclear whether the bleeding propensity correlates with platelet size, maturity or specific activity. Disease modifiers that foster or mitigate bleeding (e.g. Factor VIIIc, \(\alpha\)-granule content) have not been identified. Vascular inflammation promotes thrombocytopenic bleeding; thus, endothelial function merits further study. There is also no biochemical explanation for the marked fatigue that may be associated with low platelet counts.

\textit{Risk of thrombosis.} There is no consensus whether ITP is intrinsically a procoagulant disorder\textsuperscript{121} especially during rapid platelet response, manifested by platelet activation and release of platelet microparticles. As discussed, the literature is conflicting whether co-existing APLA predispose to thrombosis. Absent compelling data, these concerns mitigate in favor of treating to attain a hemostatic, but not a normal, platelet count in most patients and to consider use of aspirin in patients at risk for thrombosis who attain stable counts > 50,000/\(\mu\)L.

\textbf{PERSPECTIVE.} Essentially all studies of incidence, demographics, pathophysiology and treatment address ITP as a single entity. Yet, lessons learned from secondary forms suggest primary ITP is heterogeneous as well. Primary idiopathic disease will comprise an ever-decreasing proportion of patients as specific inciting events and immune defects are better identified. Improved stratification predicated on systematically identified tolerance checkpoint defects, dysfunctional auxiliary pathways and inciting antigens will help define prognosis and target intervention. What is lacking
because of the highly specialized nature of scientific research is the capacity to study the same cohort of patients for T- and B-cell repertoire, genetic markers of immune susceptibility genes, antibody specificity and avidity, platelet kinetics, platelet proteome and longitudinal outcome. More rapid progress requires a consortium to assemble a large international cohort for prospective study and sharing of sequentially obtained, archived and clinically annotated samples. ITP provides an opportunity to further our understanding of how otherwise healthy individuals generate tissue-specific autoantibodies.

ACKNOWLEDGEMENTS. NIH U01 DK 070430 and R01 DE017590 and a grant from Alliance for Lupus Research to ELP, HL081012 to DBC and NIH 1U01 HL72196-01-05 NIH 1U01 HL72196-01, NIH UL1 RR024996 and a grant from the Children's Cancer and Blood Foundation to JBB.

AUTHORSHIP CONTRIBUTIONS. All authors contributed directly to the literature review and to the drafting of the manuscript itself.

CONFLICT OF INTEREST DISCLOSURE. Cines--Consultant for Amgen, Glaxo Smith Kline, Baxter, Biogen, Syntoxonix. Liebman--Research support: Amgen, Glaxo Smith Kline, Immunomedics; Consulting: Amgen, Glaxo Smith Kline, Baxter. Bussel--Owns stock valued at greater than $10k but less than $100k in Amgen and Glaxo Smith Kline; Advisory boards: Amgen, Glaxo Smith Kline, Ligand, Baxter; Clinical research support: Baxter, Cangene, Amgen, Glaxo Smith Kline, Eisai, Ligand, Sysmex, Genzyme. Luning Prak--None.
REFERENCES


Legends

Figure 1. Estimated fraction of the various forms of secondary ITP based on clinical experience of the authors. The incidence of *H. pylori* ranges from approximately 1% in the US to 60% in Italy and Japan. The incidence of HIV and Hepatitis C approximates 20% in some populations. Miscellaneous causes of immune thrombocytopenia, e.g. drugs that lead to the production of autoantibodies, post-transfusion purpura, myelodysplasia and other conditions are not discussed further in this review. ALPS: Autoimmune lymphoproliferative syndrome; post-tx: post bone marrow or solid organ transplantation; SLE: Systemic lupus erythematosus; APS: Antiphospholipid syndrome; CLL: Chronic lymphocytic leukemia; CVID: Common variable immune deficiency. In the absence of a systematic analysis of the incidence of secondary ITP, the data shown represent our combined assessment based on experience and reading of the literature. Professional illustration by Paulette Dennis.

![Figure 1: Estimated fraction of the various forms of secondary ITP based on clinical experience of the authors.](image)

Figure 2. B-Cell Tolerance Checkpoints and Loss of Self-Tolerance in Different forms of Secondary ITP. Tolerance pathways are denoted by green dashed lines. Solid blue lines indicate normal B-cell developmental stages. Where failures in central and peripheral B-cell tolerance might occur in secondary forms of ITP are shown by the solid pink lines. Central B-lymphocyte tolerance checkpoints operate during primary cell maturation in the bone marrow and include clonal deletion and receptor editing. Crosslinking of membrane bound antibodies on immature B-cells leads to apoptosis.  

![Figure 2: B-Cell Tolerance Checkpoints and Loss of Self-Tolerance in Different forms of Secondary ITP.](image)
Antigen receptor specificity is also revised by receptor editing, i.e. the continuation or re-initiation of antibody gene rearrangement, usually at light chain loci, in lymphocytes that already have functional antibody. Receptor editing can change a self-reactive light chain (shown in pink) to a non-self reactive light chain (shown in purple). Peripheral tolerance checkpoints monitor and alter the repertoire in lymphocytes that have exited from primary lymphoid organs. Even if central tolerance is perfect, there is a need to regulate peripheral tolerance because somatic mutation can randomly generate autoreactive specificities. Somatic mutations are shown as pink circles on the heavy and light chain V-regions. Heavy chain isotype switching (which usually accompanies somatic mutation during an immune response) is shown by the change in color of the heavy chain constant region from green to blue. Anergy and death of lymphocytes after an immune response also contribute to peripheral tolerance. Immune stimulation with a pathogen that mimics self-antigen (molecular mimicry) can also lead to a loss of peripheral tolerance and feed into the anti-self ITP pathway. Peripheral AS cells in ITP can arise either primarily, through a defect in central or early tolerance checkpoints, or secondarily as a result of immune stimulation (see text). Autoreactive peripheral B-lymphocytes in ITP can include memory cells and plasma cells. Due to space constraints, only the activated cell arising from an immune response for the ITP pathway (not the plasmablast, memory cell or plasma cell) is shown. AS = anti-self (autoreactive). NS = non-self reactive. Ag = antigen. Professional illustration by Paulette Dennis.
Figure 3. Relationship between tolerance defect(s) and clinical outcome in secondary ITP. The abscissa indicates whether platelets are the sole hematopoietic lineage affected (right) or whether there is often concurrent hemolytic anemia and immune neutropenia (left). The ordinate indicates responsiveness to treatment of the inciting infection. The proposed corresponding tolerance checkpoint defects are given in shaded boxes at the base of the figure. All of the disease abbreviations are defined in the text. Professional illustration by Paulette Dennis.
Figure 4. Evolution of antiplatelet antibodies after *H pylori* infection. Platelets may be activated by binding of first-generation *H pylori* antibodies (1) to platelet FcγIIA or through an interaction between *H pylori*-bound von Willebrand factor (VWF) and platelet glycoprotein IB (gpIB). Activation may promote platelet clearance and antigen presentation, which augments production of antibacterial antibodies. Somatic mutation may lead to the development of second-generation antibodies (2) that recognize either bacterially derived factors that bind to platelets (3) or that cross-react with platelet antigens (4). Improved mucosal permeability or bacterial eradication with proton-pump inhibitors and antibiotics may initiate the clinical response in patients with anti–*H pylori* antibodies (early response), which may be followed by a decrease in bacterial antigen.
and reduction in the titer of cross-reacting antibody (late durable response). In patients
with protracted disease unresponsive to antibiotic eradication, antibodies to \textit{H pylori} may
have undergone additional somatic mutations (third-generation antibodies); (5) that lose
their reactivity with the inciting antigen, but retain platelet reactivity (6) leading to early
relapse or no response. APC indicates antigen-presenting cell. Antibodies (light chains,
heavy chains, isotype switching and somatic mutations) are drawn as in Figure 2.
Modified and reprinted from \textit{Blood} with permission. Professional illustration by Paulette
Dennis and Kenneth Probst.
The ITP syndrome: pathogenic and clinical diversity

Douglas B. Cines, James B. Bussel, Howard A. Liebman and Eline T. Luning Prak